Antibody-drug conjugates nonclinical support: From early to late nonclinical bioanalysis using ligand-binding assays

Bioanalysis

Volumn 7, Issue 13, 2015, Pages 1605-1617

  Kumar, Seema ^a   King, Lindsay E ^b   Clark, Tracey H ^b   Gorovits, Boris ^a  

^a Pfizer Biotherapeutics RandD   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BIOLOGICAL PRODUCT; CYTOTOXIC AGENT; UNCLASSIFIED DRUG; LIGAND; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; DEVELOPMENTAL STAGE; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PHYSICAL CHEMISTRY; RECEPTOR BINDING ASSAY; VALIDATION STUDY; BIOASSAY; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; LIGANDS;

EID: 84938306828     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.107     Document Type: Article

References (33)

1. Hamblett KJ, Senter PD, Chace DF et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10(20), 7063-7070 (2004
2. Xie H, Audette C, Hoffee M et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 308(3), 1073-1082 (2004
3. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26(8), 925-932 (2008
4. Baldwin AD, Kiick KL. Tunable degradation of maleimidethiol adducts in reducing environments. Bioconjug. Chem. 22(10), 1946-1953 (2011
5. Shen BQ, Bumbaca D, Saad O et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr. Drug Metab. 13, 901-910 (2012
6. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30(2), 184-189 (2012
7. Strop P, Shu-Hui L et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20(2), 161-167 (2013
8. Gorovits B, Alley S, Bilic S et al. Bioanalysis of antibody- drug conjugates. AAPS ADC working group position paper. Bioanalysis 5(9), 997-1006 (2013
9. Kaur S, Xu K, Saad OM et al. Bioanalytical assay strategies for the development of antibody drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013
10. Dufield D, Neubert H, Garofolo F et al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN and regulatory agencies input). Bioanalysis 6(23), 3237-3249 (2014
11. Keyang Xu, Luna Liu, Randall Dere et al. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis 5(9), 1057-1071 (2013
12. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm. Res. 29(9), 2354-2366 (2012
13. Sauerborn M, van Dongen W. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates. BioDrugs 28(4), 383-391 (2014
14. King LE, Leung S, Ray C. Discovery fit-for-purpose ligandbinding PK assays: whats really important? Bioanalysis 5(12), 1463-1466 (2013
15. Stephan JP, Chan P, Lee C et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 19(8), 1673-1683 (2008
16. Stephan JP, Kozak KR, Wong WLT. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6), 677-700 (2011
17. Kozak KR, Tsai SP, Fourie-ODonohue A et al. Total antibody quantification for MMAE-conjugated antibody-drug conjugates: impact of assay format and reagents. Bioconjug. Chem. 24(5), 772-779 (2013
18. Dowell JA, Korth-Bradley J, Liu H et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41, 1206-1214 (2001
19. Dijoseph JF, Armellino DC, Boghaert ER et al. Antibodytargeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5), 1807-1814 (2004
20. Dere R, Yi JH, Lei C et al. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5, 1025-1040 (2013
21. Hussain A, Gorovits B, Leal M et al. PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability. Bioanalysis 6(1), 21-32 (2014
22. Tuck MK, Chan DW, Chia D et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 8(1), 113-117 (2009
23. Mitchell BL, Yasui Y, Li CI et al. Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry based biomarker discovery projects. Cancer Inform. 1, 98-104 (2005
24. Kelley M, Ahene AB, Gorovits B. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J. 3, 646-658 (2013
25. Stevenson L, Amaravadi L, Myler H et al. White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity). Bioanalysis 6(24), 3355-3368 (2014
26. US FDA. Guidance for Industry: Bioanalytical Method Validation. Center for Drug Evaluation and Research. www.fda.gov
27. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify total and free therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011
28. Wada R, Erickson HK, Lewis Phillips GD et al. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother. Pharmacol. 74(5), 969-980 (2014
29. Bender B, Leipold DD, Xu K et al. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 16(5), 994-1008 (2014
30. Wang L, Amphlett G, Blattler WA et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 14(9), 2436-2446 (2005
31. Panowksi S, Bhakta S, Raab H et al. Site-specific antibody drug conjugates for cancer therapy. MAbs 6(1), 34-45 (2014
32. Leary BA, Lawrence-Henderson R, Mallozzi C et al. Bioanalytical platform comparison using a generic human IgG PK assay format. J. Immunol. Methods 397(1-2), 28-36 (2013
33. Sailstad JM, Amaravadi L, Clements-Egan AA et al. White paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. 16(3), 488-98 (2014